Epilepsy

Epilepsy

IBE/Pranab Basak
In low- and middle-income countries, early death among people with epilepsy is significantly higher than in high-income countries.

Epilepsy is one of the most common neurological disorders worldwide, affecting approximately 52 million people, including up to 1% of children. The burden is particularly high in low- and middle-income countries (LMICs), where access to appropriate treatment remains a major challenge. Although several antiseizure medicines are included in the WHO Model List of Essential Medicines for Children (EMLc), limited availability, affordability and registration of age-appropriate formulations continue to restrict access to effective treatment. In addition, children often require careful dose titration, highlighting the importance of formulations that allow flexible and accurate dosing without the need to manipulate adult products.

The WHO Paediatric Drug Optimization (PADO) meeting for epilepsy, held on 1–2 July 2025, identified priorities to improve access to existing antiseizure medicines, accelerate the development of optimized paediatric formulations and promote timely investigation of emerging treatments. The PADO access list prioritized improved availability and affordability of existing paediatric formulations of valproic acid and lacosamide, particularly in LMICs. The priority list identified levetiracetam, clobazam and vigabatrin, highlighting the need for age-appropriate formulations and lower strengths to support accurate dose titration, improve treatment acceptability and reduce medicine wastage.

The PADO watch list included cenobamate, a treatment already approved for adults and used off-label in children, alongside four investigational compounds with potential for future paediatric development.

Research priorities included generating robust paediatric efficacy and safety evidence for cenobamate and ensuring early inclusion of young children, including neonates, in clinical studies to account for age-related differences in treatment response in this population. PADO-epilepsy also emphasized the importance of optimizing age-appropriate formulation design from the outset, particularly to accommodate dose titration and avoid delays in access.

Portfolio products

10 products · PADO-epilepsy
● Access list: 2    ● Priority list: 3    ● Watch list: 5
2 Access
3 Priority
5 Watch

PADO-epilepsy access list 2
Valproic acid
Modified-release granule formulations 50 mg pre-dosed sachet
Lacosamide
Tablets: 50 mg, 100 mg, 150 mg, 200 mg
Oral liquid 10 mg/mL
PADO-epilepsy priority list 3
Levetiracetam
Oral dosage form (25 mg granules for oral solution or 50 mg scored tablets for oral suspension)
Clobazama
Oral, age-appropriate dosage form that allows for lower doses (titration), such as dispersible tablets (preferably 5 mg scored, dispersible tablets)
Vigabatrina
250 mg sachet good compromise between dose flexibility and reduction of waste
PADO-epilepsy watch list 5
Cenobamate
Approved for epilepsy in adults but not studied in children; currently used off-label in paediatrics, with a clear need to promote paediatric studies.

Promote the development of oral, age-appropriate dosage form that allows for lower doses (titration), such as dispersible tablets.
Azetukalnerb, BHV 7000b, Carisbamateb, Bexicaserinc
a Clobazam and vigabatrin are approved for an epilepsy indication and have been studied in children; they have not been reviewed by WHO for inclusion in guidance documents.
b Azetukalner, BHV 7000 and carisbamate are new chemical entities that are being investigated for an epilepsy indication, but ongoing clinical studies do not include children.
c Bexicaserin is a new chemical entity that is being investigated in children down to 2 years of age.

PADO report

Paediatric drug optimization for epilepsy: meeting report, 1-2 July 2025
The PADO for epilepsy exercise aimed to support the identification of short- and long term priorities for epilepsy medicines for the paediatric age group,...

Contact

Rodrigo Cataldi
Email: cataldir@who.int

Related publications

Mental Health Gap Action Programme (mhGAP) guideline for mental, neurological and substance use disorders: executive summary

This guideline includes 48 updated and new evidence-based recommendations related to MNS conditions. The guideline is targeted towards non-specialized...

Improving access to medicines for neurological disorders

Neurological disorders are the leading cause of disability globally and access to essential medicines for neurological disorders remains a critical global...

News